Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD

Journal of the American Society of Nephrology

Volumn 26, Issue 5, 2015, Pages 1138-1149

  Labonté, Eric D ^a   Carreras, Christopher W ^a   Leadbetter, Michael R ^a   Kozuka, Kenji ^a   Kohler, Jill ^a   Koo McCoy, Samantha ^a   He, Limin ^a   Dy, Edward ^a   Black, Deborah ^a   Zhong, Ziyang ^a   Langsetmo, Ingrid ^a   Spencer, Andrew G ^a   Bell, Noah ^a   Deshpande, Desiree ^a   Navre, Marc ^a   Lewis, Jason G ^a   Jacobs, Jeffrey W ^a   Charmot, Dominique ^a  

^a Ardelyx Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; NTX 3572; NTX 792; ORTHOPHOSPHATE P 33; PHOSPHATE; PHOSPHORUS; PROTEIN INHIBITOR; SODIUM; SODIUM PROTON EXCHANGE PROTEIN 3; SODIUM PROTON EXCHANGE PROTEIN 3 INHIBITOR; TENAPANOR; UNCLASSIFIED DRUG; ISOQUINOLINE DERIVATIVE; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER 3; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; FECES LEVEL; GASTROINTESTINAL ABSORPTION; HEART HYPERTROPHY; HUMAN; HUMAN CELL; HYPERPHOSPHATEMIA; IC50; KIDNEY FUNCTION; MALE; NONHUMAN; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATE TRANSPORT; PHOSPHATE URINE LEVEL; PHOSPHORUS ABSORPTION; PRIORITY JOURNAL; RAT; RAT MODEL; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; CALCINOSIS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GASTROINTESTINAL TRACT; METABOLISM; RANDOMIZATION; RENAL INSUFFICIENCY, CHRONIC; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; CALCINOSIS; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; ISOQUINOLINES; MALE; PHOSPHORUS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; SODIUM; SODIUM-HYDROGEN ANTIPORTER; SULFONAMIDES;

EID: 84929303170     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014030317     Document Type: Article

References (37)

1. Prié D, Ureña Torres P, Friedlander G: Latest findings in phosphate homeostasis. Kidney Int 75: 882-889, 2009
2. Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378, 2011
3. Collins AJ, Foley RN, Gilbertson DT, Chen SC: The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 4[Suppl 1]: S5-S11, 2009
4. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
5. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A: Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770-779, 2004
6. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44[Suppl 2]: 34-38, 2004
7. Lynch KE, Lynch R, Curhan GC, Brunelli SM: Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 6: 620-629, 2011
8. Kestenbaum B: Phosphate metabolism in the setting of chronic kidney disease: Significance and recommendations for treatment. Semin Dial 20: 286-294, 2007
9. Cozzolino M, Mazzaferro S, Brandenburg V: The treatment of hyperphosphataemia in CKD: Calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant 26: 402-407, 2011
10. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661, 2003
11. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407-1415, 2012
12. Chue CD, Townend JN, Moody WE, Zehnder D, Wall NA, Harper L, Edwards NC, Steeds RP, Ferro CJ: Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 24: 842-852, 2013
13. Marks J, Debnam ES, Unwin RJ: The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease. Curr Opin Nephrol Hypertens 22: 481-487, 2013
14. Hattenhauer O, Traebert M, Murer H, Biber J: Regulation of small intestinal Na-P(i) type IIb cotransporter by dietary phosphate intake. Am J Physiol 277: G756-G762, 1999
15. Katai K, Miyamoto K, Kishida S, Segawa H, Nii T, Tanaka H, Tani Y, Arai H, Tatsumi S, Morita K, Taketani Y, Takeda E: Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. Biochem J 343: 705-712, 1999
16. Marks J, Srai SK, Biber J, Murer H, Unwin RJ, Debnam ES: Intestinal phosphate absorption and the effect of vitamin D: A comparison of rats with mice. Exp Physiol 91: 531-537, 2006
17. Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, Kozuka K, Kohler J, Koo-McCoy S, He L, Bell N, Tabora J, Joly KM, Navre M, Jacobs JW, Charmot D: Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med 6: 227ra36, 2014
18. Charmot D, Jacobs J, Spencer A, Raab M, Rosenbaum D: RDX5791, a non-systemic NHE3 inhibitor for the treatment of fluid and sodium overload, shifts sodium excretion from urine to feces in healthy subjects. Presented at the ERA-EDTA Conference, Paris, April 26-29 2012
19. Charmot D, Jacobs J, Leadbetter M, Navre M, Carreras C, Bell N: Compounds and methods for inhibiting NHE- mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders. World Intellectual Property Organization WO2010078449A2: (examples 202 and 203 for tenapanor and NTX792, resp.) 2010
20. Bell N, Carreras C, Charmot D, Chen T, Leadbetter M, Jacobs J, Lewis J: Compounds and Methods for Inhibiting NHE-Mediated Antiport in the treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders. World Intellectual Property Organization WO2014029984: 2014
21. Tonelli M, Pannu N, Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 362: 1312-1324, 2010
22. Burke SK, Slatopolsky EA, Goldberg DI: RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 12: 1640-1644, 1997
23. Pennick M, Poole L, Dennis K, Smyth M: Lanthanum carbonate reduces urine phosphorus excretion: Evidence of high-capacity phosphate binding. Ren Fail 34: 263-270, 2012
24. Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M: Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17: 795-804, 2006
25. Andrukhova O, Zeitz U, Goetz R, Mohammadi M, Lanske B, Erben RG: FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51: 621-628, 2012
26. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5: 286-291, 2010
27. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C: Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial. Am J Kidney Dis 59: 177-185, 2012
28. Ohnishi M, Nakatani T, Lanske B, Razzaque MS: In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2: 583-590, 2009
29. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M: The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73: 300-307, 2008
30. Toussaint ND, Pedagogos E, Tan SJ, Badve SV, Hawley CM, Perkovic V, Elder GJ: Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology (Carlton) 17: 433-444, 2012
31. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A: Phosphate: A stealthier killer than previously thought? Cardiovasc Pathol 21: 372-381, 2012
32. Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa T: Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 85: 1103-1111, 2014
33. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St. John Sutton M, Ojo A, Gadegbeku CDi Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011
34. Paradiso AM, Tsien RY, Machen TE: Na+-H+ exchange in gastric glands as measured with a cytoplasmic-trapped, fluorescent pH indicator. Proc Natl Acad Sci U S A 81: 7436-7440, 1984
35. Fernandes I, Béliveau R, Friedlander G, Silve C: NaPO(4) cotransport type III (PiT1) expression in human embryonic kidney cells and regulation by PTH. Am J Physiol 277: F543-F551, 1999
36. Bijsterbosch MK, Duursma AM, Bouma JM, Gruber M: The plasma volume of the Wistar rat in relation to the body weight. Experientia 37: 381-382, 1981
37. Labonté ED, Howles PN, Granholm NA, Rojas JC, Davies JP, Ioannou YA, Hui DY: Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Biochim Biophys Acta 1771: 1132-1139, 2007